CDK4/6 Inhibition Stabilizes Disease in Patients With P16-Null Non-Small Cell Lung Cancer and Is Synergistic With mTOR Inhibition

Oncotarget - United States
doi 10.18632/oncotarget.26424
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Dual Inhibition of EGFR and mTOR Pathways in Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

CDK4/6 Inhibition in Cancer: The Cell Cycle Splicing Connection

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2019English

Quantitative P16 and ESR1 Methylation in the Peripheral Blood of Patients With Non-Small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
1994English

Combining Chemotherapy With Epidermal Growth Factor Receptor Inhibition in Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2012English

Inhibition of mTOR by Temsirolimus Contributes to Prolonged Survival of Mice With Pleural Dissemination of Non-Small-Cell Lung Cancer Cells

Cancer Science
Cancer ResearchMedicineOncology
2011English

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Targeting CDK4/6 in Patients With Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2016English

LSH Interacts With and Stabilizes GINS4 Transcript That Promotes Tumourigenesis in Non-Small Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy